Back to search results

[Ga-68]MTP220 PET for Pancreatic and Head and Neck Cancers

This study is testing a new diagnostic tool called [Ga-68]MTP220 PET/CT Scan for people with pancreatic cancer or head and neck cancer. This tool uses a special tracer drug, [Ga-68]MTP220, which is not yet approved by the FDA. Researchers want to see how this drug spreads in the body (biodistribution) and how much radiation it gives off (dosimetry) to make sure it's safe and effective for diagnosing these cancers. You may be able to join if you are over 18, have a recent diagnosis of pancreatic or head and neck cancer, and haven't started treatment yet. The study aims to find out if [Ga-68]MTP220 can help detect these cancers earlier. The current recruitment status is unclear, and the study plans to enroll 12 participants.

Study design
This is an interventional study, but the phase is not specified. It plans to enroll 12 participants.
What's involved
You would receive a single injection of [Ga-68]MTP220 followed by PET/CT imaging at three points. These procedures will take about 2.5 hours.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07026981

[Ga-68]MTP220 PET for Biodistribution and Efficacy in Pancreatic Cancer and Head and Neck Cancers

Not Yet Recruiting
EARLY_PHASE1Ages 18+InterventionalDiagnostic
Qiubai Li
~12 participants
Updated 2025-08-08 on ClinicalTrials.gov
What's tested:[Ga-68]MTP220 PET/CT Scan

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Biodistribution of [Ga-68]MTP220 in patients with pancreatic cancer and head and neck cancers, as measured by standardized uptake value (SUV) mean and maximum
Measured over Time it takes to do imaging study procedures, about 2.5 hours
+1 more outcome measured

Conditions

Head and Neck Cancer
Pancreatic Cancer
Cancer Pancreas

Explore related trials

Malignant Head and Neck NeoplasmPancreatic Carcinoma

Where it's being run

1 sites across 1 states
Ohio1

Study leadership

  • Qiubai Li, MD · PRINCIPAL_INVESTIGATOR · Case Comprehensive Cancer Center, University Hospitals

Who to contact

Lauren Hahn
[email protected]
216-844-9312
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants older than 18 years old
Prior biopsy showing pancreatic or head and neck malignancy
Participants have been newly diagnosed and not yet received definitive therapy (including surgery, radiation therapy, or systemic therapy).
Able and willing to provide written informed consent before any protocol-specific procedures are undertaken
Participants willing and able to undergo a PET/CT
Participants with severe hepatic and renal dysfunction (Total bilirubin \> 3 mg/dL, Albumin \< 2.8 g/dL, INR \> 2.3 (or prolonged PT), presence of ascites or hepatic encephalopathy (Grade III-IV) End-Stage Renal Disease (ESRD) or eGFR \< 30 mL/min/1.73m², Serum creatinine \> 4 mg/dL or rapidly rising, Need for dialysis (hemodialysis or peritoneal dialysis), uremic symptoms)
Participants \< 18 years old
Participants who refuse to give or are unable to sign the informed consent
Anti-cancer treatment (chemotherapy and/or radiation therapy) within the last 2 weeks
Participants unable to withstand or undergo PET/CT
Pregnant or breast feeding women.

What this trial measures

  • Biodistribution of [Ga-68]MTP220 in patients with pancreatic cancer and head and neck cancers, as measured by standardized uptake value (SUV) mean and maximumTime it takes to do imaging study procedures, about 2.5 hours
  • Radiation dosimetry of [Ga-68]MTP220, as measured by dosimetry calculations performed using site softwareTime it takes to do imaging study procedures, about 2.5 hours